NEW YORK (GenomeWeb News) – Metabolon said today that Pfizer’s Bioprocess R&D Group is using the firm’s metabolomics technology in analyzing cellular metabolism in the biopharmaceutical production process.
 
Pfizer will use the biochemical profiling technology, called mVision, to analyze samples from bioreactors, said Research Triangle Park, NC-based Metabolon. The tool will enable researchers to identify essential nutrients that are depleted and unearth toxic metabolites in the cells.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.